1
|
Angeli A, Ferraroni M, Capasso C, Supuran CT. The dopamine D 2 receptors antagonist Veralipride inhibits carbonic anhydrases: solution and crystallographic insights on human isoforms. Chem Asian J 2024; 19:e202400067. [PMID: 38334332 DOI: 10.1002/asia.202400067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 02/02/2024] [Accepted: 02/05/2024] [Indexed: 02/10/2024]
Abstract
The inhibitory effects of veralipride, a benzamide-class antipsychotic acting as dopamine D2 receptors antagonist incorporates a primary sulfonamide moiety and was investigated for its interactions with carbonic anhydrase (CA) isoforms. In vitro profiling using the stopped-flow technique revealed that veralipride exhibited potent inhibitory activity across all tested hCA isoforms, with exception of hCA III. Comparative analysis with standard inhibitors, acetazolamide (AAZ), and sulpiride, provided insights for understanding the relative efficacy of veralipride as CA inhibitor. The study reports the X-ray crystal structure analysis of the veralipride adduct with three human (h) isoforms, hCA I, II, and CA XII mimic, allowing the understanding of the molecular interactions rationalizing its inhibitory effects against each isoform. These findings contribute to our understanding of veralipride pharmacological properties and for the design of structural analogs endowed with polypharmacological properties.
Collapse
Affiliation(s)
- Andrea Angeli
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy
| | - Marta Ferraroni
- Department of Chemistry "Ugo Schiff", University of Florence, Via della Lastruccia 3-13, I-50019, Sesto Fiorentino, Florence, Italy
| | | | - Claudiu T Supuran
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy
| |
Collapse
|
2
|
McVicker R, O’Boyle NM. Chirality of New Drug Approvals (2013-2022): Trends and Perspectives. J Med Chem 2024; 67:2305-2320. [PMID: 38344815 PMCID: PMC10895675 DOI: 10.1021/acs.jmedchem.3c02239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 01/18/2024] [Accepted: 01/24/2024] [Indexed: 02/23/2024]
Abstract
Many drugs are chiral with their chirality determining their biological interactions, safety, and efficacy. Since the 1980s, there has been a regulatory preference to bring single enantiomer to market. This perspective discusses trends related to chirality that have developed in the past decade (2013-2022) of new drug approvals. The EMA has not approved a racemate since 2016, while the average for the FDA is one per year from 2013 to 2022. These 10 include drugs which have been previously marketed elsewhere for several decades, analogues of pre-existing drugs, or drugs where the undefined stereocenter does not play a role in therapeutic activity. Two chiral switches were identified which were both combined with drug repurposing. This combination strategy has the potential to produce therapeutically valuable drugs in a faster time frame. Two class III atropisomers displaying axial chirality were approved between 2013 and 2022, one as a racemate and one as a single enantiomer.
Collapse
Affiliation(s)
- Rebecca
U. McVicker
- School
of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences
Institute, Trinity College Dublin, 152−160 Pearse Street, Dublin 2, D02 R590, Ireland
- Gamlen
Tableting Ltd, 3 Stanton
Way, London SE26 5FU, United Kingdom
| | - Niamh M. O’Boyle
- School
of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences
Institute, Trinity College Dublin, 152−160 Pearse Street, Dublin 2, D02 R590, Ireland
| |
Collapse
|
3
|
Donahue TJ, Hillhouse TM, Webster KA, Young R, De Oliveira EO, Porter JH. Examination of the mechanisms underlying the discriminative stimulus properties of the atypical antipsychotic amisulpride. Behav Pharmacol 2024; 35:47-54. [PMID: 38375659 DOI: 10.1097/fbp.0000000000000760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2024]
Abstract
Amisulpride is an atypical benzamide antipsychotic/antidepressant, whose mechanism of action is thought to depend mainly on dopamine D2/3 receptor activity, but also with some serotonin 5-HT2B/7 effects. The present study examined the role of D2/3 receptors and 5-HT2B/7 receptors in amisulpride's discriminative stimulus. Selective agonists and antagonists of the above receptors were tested in adult, male C57BL/6 mice trained to discriminate 10 mg/kg amisulpride from vehicle in a two-lever drug discrimination assay. After acquisition of the two-lever discrimination, the amisulpride generalization curve yielded an ED50 = 0.56 mg/kg (95% CI = 0.42-0.76 mg/kg). Substitution tests found that the D2/3 antagonist raclopride (62.7% Drug Lever Responding), D2/3 agonist quinpirole (56.6% DLR), 5-HT7 agonist LP-44 (50.1% DLR) and 5-HT7 antagonist SB-269970 (36.7% DLR) produced various degrees of partial substitution for the amisulpride stimulus, whereas the 5-HT2B agonist BW 723C86 (17.9% DLR) and 5-HT2B antagonist SB-204741 (21.1% DLR) yielded negligible amisulpride-like effects. In combination tests with amisulpride, quinpirole decreased percent responding from 98.3% to 57.0% DLR, LP-44 decreased percent responding from 97.6% to 76.7% DLR, and BW 723C86 reduced percent responding from 95.66% to 74.11% DLR. Taken together, the results from stimulus generalization and antagonism studies suggest that amisulpride has a complex discriminative cue that involves mainly mixed D2/3 receptor antagonist/agonist effects and, to a lesser degree, mixed 5-HT7 receptor agonist/antagonist and perhaps 5-HT2B receptor antagonist effects.
Collapse
Affiliation(s)
- Timothy J Donahue
- Department of Psychology, Virginia Commonwealth University, Richmond, Virginia
| | - Todd M Hillhouse
- Department of Psychology, University of Wisconsin - Green Bay, Green Bay, Wisconsin
| | | | - Richard Young
- Department of Medicinal Chemistry, Virginia Commonwealth University
| | | | - Joseph H Porter
- Department of Psychology, Virginia Commonwealth University, Richmond, Virginia
| |
Collapse
|
4
|
Jahreis K, Brüge A, Borsdorf S, Müller FE, Sun W, Jia S, Kang DM, Boesen N, Shin S, Lim S, Koroleva A, Satała G, Bojarski AJ, Rakuša E, Fink A, Doblhammer-Reiter G, Kim YK, Dityatev A, Ponimaskin E, Labus J. Amisulpride as a potential disease-modifying drug in the treatment of tauopathies. Alzheimers Dement 2023; 19:5482-5497. [PMID: 37218673 DOI: 10.1002/alz.13090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 03/07/2023] [Accepted: 03/08/2023] [Indexed: 05/24/2023]
Abstract
INTRODUCTION Hyperphosphorylation and aggregation of the microtubule-associated protein tau cause the development of tauopathies, such as Alzheimer's disease and frontotemporal dementia (FTD). We recently uncovered a causal link between constitutive serotonin receptor 7 (5-HT7R) activity and pathological tau aggregation. Here, we evaluated 5-HT7R inverse agonists as novel drugs in the treatment of tauopathies. METHODS Based on structural homology, we screened multiple approved drugs for their inverse agonism toward 5-HT7R. Therapeutic potential was validated using biochemical, pharmacological, microscopic, and behavioral approaches in different cellular models including tau aggregation cell line HEK293 tau bimolecular fluorescence complementation, primary mouse neurons, and human induced pluripotent stem cell-derived neurons carrying an FTD-associated tau mutation as well as in two mouse models of tauopathy. RESULTS Antipsychotic drug amisulpride is a potent 5-HT7R inverse agonist. Amisulpride ameliorated tau hyperphosphorylation and aggregation in vitro. It further reduced tau pathology and abrogated memory impairment in mice. DISCUSSION Amisulpride may be a disease-modifying drug for tauopathies.
Collapse
Affiliation(s)
- Kathrin Jahreis
- Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany
| | - Alina Brüge
- Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany
| | - Saskia Borsdorf
- Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany
| | - Franziska E Müller
- Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany
| | - Weilun Sun
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
| | - Shaobo Jia
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
| | - Dong Min Kang
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea
- Department of Life Sciences, Korea University, Seoul, Republic of Korea
| | - Nicolette Boesen
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul, Republic of Korea
| | - Seulgi Shin
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea
| | - Sungsu Lim
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea
| | - Anastasia Koroleva
- Department of Nanoengineering, Institute of Quantum Optics, Leibniz University Hannover, Hannover, Germany
| | - Grzegorz Satała
- Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| | - Andrzej J Bojarski
- Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| | - Elena Rakuša
- German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
| | - Anne Fink
- German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
| | | | - Yun Kyung Kim
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea
- Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| | - Alexander Dityatev
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
- Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany
- Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany
| | - Evgeni Ponimaskin
- Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany
| | - Josephine Labus
- Department of Cellular Neurophysiology, Hannover Medical School, Hannover, Germany
| |
Collapse
|
5
|
Wu J, Kwan AT, Rhee TG, Ho R, d'Andrea G, Martinotti G, Teopiz KM, Ceban F, McIntyre RS. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia. Expert Rev Clin Pharmacol 2023; 16:1085-1092. [PMID: 37864424 DOI: 10.1080/17512433.2023.2274538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Accepted: 10/19/2023] [Indexed: 10/22/2023]
Abstract
INTRODUCTION The challenges posed by treatment-resistant schizophrenia and depressive symptoms have led to ongoing difficulties despite the availability of antipsychotics and antidepressants. This review addresses the potential of amisulpride analogs, particularly SEP-4199, in addressing these challenges through enhanced efficacy and reduced side effects. AREAS COVERED This review focuses on the pharmacological profile of amisulpride analogs, exemplified by LB-102 and its derivative SEP-4199. PubMed gathered articles (up to 10 March 2023) on 'amisulpride,' 'schizophrenia,' 'bipolar disorder,' and 'major depressive disorder;' ClinicalTrials.gov tracked SEP-4199 and LB-102 trials. LB-102, a newly identified N-methylated analog of amisulpride, exhibits enhanced lipophilicity at lower doses, as demonstrated in a phase 1 study, indicating significant promise for therapeutic applications. The discovery of SEP-4199, a non-racemic analog composed of R- and S-enantiomers in an 85:15 ratio, is discussed, emphasizing its potential to enhance antidepressant effects while minimizing extrapyramidal side effects via selective D2 receptor binding. Recent phase 2 trials have demonstrated SEP-4199's efficacy in treating depressive symptoms in bipolar disorder I, capitalizing on D2-mediated anti-anhedonic and D3-mediated reward effects. EXPERT OPINION The development of SEP-4199 presents a potential breakthrough for managing depressive symptoms in bipolar disorder I. Further exploration of D2 and D3 receptor-mediated effects could lead to improved treatment strategies.
Collapse
Affiliation(s)
- Jie Wu
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
| | - Angela Th Kwan
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada
| | - Taeho Greg Rhee
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
- VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA
- Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA
| | - Roger Ho
- Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore
| | - Giacomo d'Andrea
- Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy
| | - Giovanni Martinotti
- Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy
- Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
| | - Kayla M Teopiz
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada
| | - Felicia Ceban
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | - Roger S McIntyre
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
6
|
Picard B, Fukuyama T, Ryu I. Phosphine-Free Aminocarbonylation Using Pd/DBU Catalyst: Carbonylative Coupling of Aryl Iodides and Amines. J Org Chem 2022; 88:5220-5225. [PMID: 36525565 DOI: 10.1021/acs.joc.2c02369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
An improved carbonylation method allowing amide bond formation between aryl iodides and aromatic amines is presented. In contrast to usual methods based on Pd catalysis, this method does not require a phosphine ligand. The catalyst system simply employs bis(dibenzylideneacetone)palladium (0.5 mol %) and DBU (10 mol %). The method was applied to the synthesis of various aromatic amides from aryl iodides and amines, and was scaled to gram order synthesis under as low as 1 atm of carbon monoxide.
Collapse
Affiliation(s)
- Baptiste Picard
- Organization for Research Promotion, Osaka Metropolitan University, Sakai, Osaka 599-8531, Japan
| | - Takahide Fukuyama
- Department of Chemistry, Graduate School of Science, Osaka Metropolitan University, Sakai, Osaka 599-8531, Japan
| | - Ilhyong Ryu
- Organization for Research Promotion, Osaka Metropolitan University, Sakai, Osaka 599-8531, Japan
- Department of Applied Chemistry, National Yang Ming Chiao Tung University (NYCU), Hsinchu 30010, Taiwan
| |
Collapse
|
7
|
Biernat L, Grattan VT, Hixon MS, Prensky Z, Vaino AR. A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D 2/3/5-HT 7 inhibitor. Psychopharmacology (Berl) 2022; 239:3009-3018. [PMID: 35841422 DOI: 10.1007/s00213-022-06185-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 06/26/2022] [Indexed: 11/29/2022]
Abstract
LB-102 is an N-methylated analogue of amisulpride under development to treat schizophrenia. LB-102 was evaluated in a Phase 1, double-blind, placebo-controlled, clinical study to evaluate safety and pharmacokinetics. This was a first-in-human study examining single and multiple doses of LB-102 administered orally in 64 healthy volunteers. Dosing in the single ascending dose (SAD) portion of the study was initially planned to be 50, 100, 200, and 400 mg, with doses in the multiple ascending dose (MAD) portion to be determined based on observations in the SAD portion. As a result of two cases of EPS (acute dystonia) at 200 mg in the MAD portion of the study, dosing of that arm was discontinued and doses for the remaining cohort were decreased to 150 mg/day. Dose escalation was guided by safety and plasma concentrations of LB-102 compared to a translational model. LB-102 was generally safe and well-tolerated, and clinical lab values were unremarkable at all doses, save for prolactin which was transiently elevated in the majority of subjects treated with LB-102; there were no clinical observations associated with the increases in prolactin elevation. There was evidence of transient QT interval prolongation at the 200 mg dose, none of which resulted in clinical observation or triggered stopping criteria. There were four instances of EPS (acute dystonia), typically associated with dopamine receptor occupancy in excess of 80%, one at 100 mg QD, one at 75 mg BID, and two at 100 mg BID. A phase 2 clinical study of LB-102 in schizophrenia patients with PANSS as primary endpoint is being planned.
Collapse
Affiliation(s)
- Lukasz Biernat
- Medpace Clinical Pharmacology LLC, 5355 Medpace Way, Cincinnati, OH, USA.,Eli Lilly and Co, Indianapolis, IN, USA
| | - Vincent T Grattan
- LB Pharmaceuticals Inc, 575 Madison Ave., 10th flr, New York, NY, USA
| | - Mark S Hixon
- Mark S. Hixon Consulting LLC, 11273 Spitfire Road, San Diego, CA, USA
| | - Zachary Prensky
- LB Pharmaceuticals Inc, 575 Madison Ave., 10th flr, New York, NY, USA
| | - Andrew R Vaino
- LB Pharmaceuticals Inc, 575 Madison Ave., 10th flr, New York, NY, USA.
| |
Collapse
|
8
|
Hopkins SC, Wilkinson S, Corriveau TJ, Nishikawa H, Nakamichi K, Loebel A, Koblan KS. Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders. Clin Pharmacol Ther 2021; 110:808-815. [PMID: 33961287 PMCID: PMC8453756 DOI: 10.1002/cpt.2282] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 03/10/2021] [Indexed: 12/04/2022]
Abstract
In contrast to the dose‐occupancy relationship in the treatment of schizophrenia, the minimal effective level of dopamine receptor 2 (D2R) blockade for antipsychotics in the treatment of bipolar depression is unknown. Lower doses aimed at reducing extrapyramidal side effects must be balanced against the need to retain the therapeutic benefit of D2R blockade on emergent cycling, mixed, manic, anxiety, and/or psychotic symptoms. Dose‐reductions intended to lower D2R blockade, however, could also decrease concomitant serotonin receptor antagonism and its potential benefit on depressive symptoms. Here, we uncoupled the potential antidepressant activity in amisulpride, driven by 5‐HT7 receptor (5‐HT7R) antagonism, from the D2R‐mediated antipsychotic activity by discovering that each enantiomer favors a different receptor. Aramisulpride was more potent at 5‐HT7R relative to esamisulpride (Ki 47 vs. 1,900 nM, respectively), whereas esamisulpride was more potent at D2R (4.0 vs. 140 nM). We hypothesized that a nonracemic ratio might achieve greater 5‐HT7R‐mediated antidepressant effects at a lower level of D2R blockade. The dose‐occupancy relationship of esamisulpride at D2R was determined by positron emission tomography (PET) imaging in human volunteers. Separately the dose‐relationship of aramisulpride was established in humans using suppression of rapid eye movement (REM) sleep as a marker of 5‐HT7R antagonism. These results led to the discovery of an 85:15 ratio of aramisulpride to esamisulpride (SEP‐4199) that maximizes the potential for antidepressant benefit of aramisulpride via 5‐HT7R and reduces esamisulpride to minimize D2R‐related extrapyramidal side effects while still retaining D2R‐mediated effects predicted to provide benefit in bipolar depression. The antidepressant efficacy of SEP‐4199 was recently confirmed in a proof‐of‐concept trial for the treatment of bipolar depression (NCT03543410).
Collapse
Affiliation(s)
- Seth C Hopkins
- Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts, USA
| | - Scott Wilkinson
- Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts, USA
| | | | - Hiroyuki Nishikawa
- Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan
| | - Keiko Nakamichi
- Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan
| | - Antony Loebel
- Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts, USA
| | | |
Collapse
|
9
|
Kucwaj-Brysz K, Latacz G, Podlewska S, Żesławska E, Handzlik J, Lubelska A, Satała G, Nitek W, Handzlik J. The relationship between stereochemical and both, pharmacological and ADME-Tox, properties of the potent hydantoin 5-HT 7R antagonist MF-8. Bioorg Chem 2020; 106:104466. [PMID: 33246603 DOI: 10.1016/j.bioorg.2020.104466] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 09/30/2020] [Accepted: 11/06/2020] [Indexed: 11/18/2022]
Abstract
This study concerns synthesis and evaluation of pharmacodynamic and pharmacokinetic profile for all four stereoisomers of MF-8 (5-(4-fluorophenyl)-3-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)-5-methylimidazolidine-2,4-dione), the previously described, highly potent 5-HT7R ligand with antidepressant activity on mice. The combination of DFT calculations of 1H NMR chemical shifts with docking and dynamic simulations, in comparison to experimental screening results, provided prediction of the configuration for one of two present stereogenic centers. The experimental data for stereoisomers (MF-8A-MF-8D) confirmed the significant impact of stereochemistry on both, 5-HT7R affinity and antagonistic action, with Ki and Kb values in the range of 3-366 nM and 0.024-99 μM, respectively. We also indicated the stereochemistry-dependent influence of the tested compounds on P-glycoprotein efflux, absorption in Caco-2 model, metabolic pathway as well as CYP3A4 and CYP2C9 activities.
Collapse
Affiliation(s)
- Katarzyna Kucwaj-Brysz
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Gniewomir Latacz
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Sabina Podlewska
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland; Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Kraków, Poland
| | - Ewa Żesławska
- Institute of Biology, Pedagogical University of Cracow, Podchorążych 2, 30-084 Kraków, Poland
| | - Jarosław Handzlik
- Faculty of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, 31-155 Kraków, Poland
| | - Annamaria Lubelska
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Grzegorz Satała
- Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Kraków, Poland
| | - Wojciech Nitek
- Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kraków, Poland
| | - Jadwiga Handzlik
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
| |
Collapse
|
10
|
Smyla N, Koch T, Eberhart LHJ, Gehling M. An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting. Expert Opin Pharmacother 2020; 21:517-522. [DOI: 10.1080/14656566.2020.1714029] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Natalia Smyla
- Department of Anaesthesiology and Intensive Care Medicine, Philipps-University Marburg, Marburg, Germany
| | - Tilo Koch
- Department of Anaesthesiology and Intensive Care Medicine, Philipps-University Marburg, Marburg, Germany
| | - Leopold HJ Eberhart
- Department of Anaesthesiology and Intensive Care Medicine, Philipps-University Marburg, Marburg, Germany
| | - Markus Gehling
- Department of Anaesthesiology and Intensive Care Medicine, Philipps-University Marburg, Marburg, Germany
- Centre for Pain Management, Kassel, Germany
| |
Collapse
|